Aethlon Medical Plans Engaging Presentations This September
Aethlon Medical's Upcoming Virtual Investor Conferences
Aethlon Medical, Inc. (NASDAQ: AEMD), a company dedicated to developing innovative therapies for cancer and serious infectious diseases, has exciting news for investors. They will be presenting at two significant virtual investor conferences in September, aimed at sharing their latest developments and engaging with the investment community.
Life Sciences Investor Forum Presentation
On September 19 and 20, Aethlon Medical's interim CEO and CFO, James Frakes, along with Dr. Steven LaRosa, the company’s Chief Medical Officer, will present an overview of the company at the Life Sciences Investor Forum. This conference will be held virtually, providing a platform for interactive engagement between investors and company management.
Details of the Life Sciences Investor Forum
The presentation is scheduled for September 19, 2024, at 1:30 pm ET. Interested investors have the opportunity to pre-register for the event, where they can ask questions directly to the management team in real-time. Additionally, an archived version of the presentation will be available after the event for those who wish to revisit the discussion.
Virtual Emerging Growth Conference Insights
Following the Life Sciences Investor Forum, Aethlon Medical will also participate in the Virtual Emerging Growth Conference on September 25, 2024. The same management team will again present crucial insights into the company’s strategic initiatives and advancements in its medical therapies.
Presentation Insights for the Emerging Growth Conference
This presentation is scheduled for September 25, 2024, at 12:35 pm ET. After this session, the floor will be opened to questions, allowing investors to engage further with Aethlon’s leadership. Questions can be sent in advance to the company, ensuring a dynamic and interactive exchange during the Q&A segment of the conference.
Understanding Aethlon Medical and Their Innovations
Aethlon Medical is pioneering the development of the Hemopurifier, a critical medical device that targets cancer and life-threatening viral infections. This innovative device has undergone multiple studies, demonstrating its capability to remove dangerous viruses and harmful exosomes from biological fluids by employing a unique lectin-based technology.
The Impact of the Hemopurifier
The Hemopurifier is recognized as a Breakthrough Device by the U.S. FDA, indicating its significant potential in treating advanced or metastatic cancers, especially in cases where patients have shown no response to conventional therapies. Furthermore, the device is also subject to an open Investigational Device Exemption (IDE) application for treating dangerous viruses lacking approved treatment options.
Company Insights and Future Directions
Aethlon Medical is committed to addressing unmet medical needs within the cancer and infectious disease landscape. The forthcoming presentations will provide valuable insights into their strategic initiatives, intended to position the company favorably in a competitive market. Investors are encouraged to engage with the leadership team during these two virtual conferences to better understand Aethlon's evolving role in healthcare innovation.
Company Contact Information
For further inquiries, investors can reach out to:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
Frequently Asked Questions
What is Aethlon Medical presenting at the conferences?
Aethlon Medical will present overviews of their company and innovations, focusing on their Hemopurifier technology.
When are the presentations scheduled?
The Life Sciences Investor Forum presentation is on September 19, and the Virtual Emerging Growth Conference is on September 25, both in 2024.
Who will be presenting on behalf of Aethlon Medical?
James Frakes, the Interim CEO and CFO, along with Dr. Steven LaRosa, Chief Medical Officer, will present at both conferences.
How can investors engage with the company?
Investors can participate in Q&A sessions during the conferences and submit questions in advance to management.
What is the purpose of the Hemopurifier?
The Hemopurifier is designed to target and remove life-threatening viruses and exosomes to support patients with cancer and severe infections.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Kinaxis Strategic Update: Leadership Changes and Growth Plans
- Impact BioMedical Inc. Successfully Completes IPO with Growth Prospects
- Kaskela Law Investigates Inari Medical for Shareholder Claims
- Affirm Set for Engaging Investor Session with Morning Brew
- Crossject Set to Reveal Financial Insights and Strategy Plans
- Impact BioMedical Inc. Celebrates Successful IPO Closure
- Factor 7 Medical Expands Horizons with Strategic Growth Moves
- LIME Painting Launches Bold Expansion Plans in New York
- Exploring the Expanding Wearable Medical Devices Industry
- EU Plans Competitiveness Fund to Boost Strategic Investment
Recent Articles
- NANO Nuclear Energy Inc Faces Class Action Lawsuit for Investors
- Newtopia's GLP-1 Support Programs: A Strategic Expansion Journey
- Exciting Assay Results Highlight Metallis Resources' Potential
- Westbridge Renewable's Dolcy Project: A Milestone in Clean Energy
- Foran Mining Secures $71 Million in Latest Financing Round
- Enhancements of Remark AI on Intel Architecture for Better Performance
- Converge Technology Solutions Achieves Secure PCI-DSS Certification
- EssilorLuxottica and Meta Forge New Horizons in Smart Eyewear
- Merck and Daiichi Sankyo Achieve Breakthrough in Lung Cancer Treatment
- Flutter Entertainment Acquires Snaitech, Strengthening Market Presence
- Palantir Technologies Partners with Nebraska Medicine to Innovate Patient Care
- Merit Medical Systems Expands Cardiac Portfolio with Strategic Acquisition
- Schlumberger Unveils Innovative Lumi AI Platform for Energy
- Société des alcools du Québec Reports Strong Q1 Financials
- DAVIDsTEA Sees Notable Growth in Q2 Fiscal 2024 Results
- Regal Rexnord Reveals Ambitious Financial Goals for 2024
- Nucor Projects Earning Insights and Strategic Moves
- Maximizing Monthly Income: Invest in FedEx for Dividends
- Ferguson Reports Fourth Quarter Performance and Future Outlook
- Personalized Compensation Trends Reshaping Employee Rewards
- Intel Corporation's Strategic Updates and Market Analysis
- Deckers Outdoor Adjusts Price Target; Positive Analyst Outlook
- Esquire Financial Hits Record Highs: Insights on Market Trends
- Cabot Corp Achieves Unprecedented Stock Surge to $107
- Exponent Inc. Reaches Milestone Stock Price with Promising Growth
- Microsoft's Dividend Boost and Buyback Strategy Leads to Growth
- Nucor Corporation Maintains Shareholder Value Amid Earnings Shift
- BofA Highlights Amazon's Strong Potential Amid Tech Partnerships
- Deckers Outdoor Stock Split and Analyst Outlook Inspire Growth
- Datasea Inc. Reports $9 Million Generated from New 5G Agreements
- Eagle Materials Achieves Historic Stock Surge to $280.04
- Federal Reserve Poised for Major Rate Adjustment Soon
- Tiny Health Strengthens Leadership with New Appointments
- U.S. Manufacturing Sees Strong Rebound With Motor Vehicles
- Legal Investigation for Shareholders: Company Breach Insights
- Analysts Urge Federal Reserve to Rapidly Implement Rate Cuts
- U.S. Home Builder Confidence Rises Amid Rate Cut Expectations
- Walmart+ Membership Growth: Unprecedented Surge Highlights Value
- Empowering IT Professionals Through Education and Community Growth
- Philip Morris Navigates Change with Sale of Vectura Group
- Innovative Parking Solutions Transform Dallas Experience
- Significant Growth: Carvana Stock Investment Insights
- What Would Your $1000 Investment in Novavax Be Worth Today?
- Revolut and Robinhood Poised to Transform DeFi Landscape
- Enhancing OEM Support with FortressONE's Latest Offerings
- Brookfield Asset Management: Strategic Moves and Market Updates
- Tilray Strengthens Craft Beer Portfolio with Key Acquisition
- Analysts Predict Major Gains for GE Vernova: Key Insights
- Insights on Reneo Pharmaceuticals and Attractive Stock Moves
- Revitalizing AsiaInfo: Edward Tian's Bold Corporate Strategy